GlobalData found that Oncology was the largest therapy area for clinical trials in...
- Lack of CMO availability threatens cell and gene therapy development
- CD47-targeted therapies: the breast cancer mop?
- Through CRISPR gene editing we can change the nature of our species
- Could groundbreaking gene therapies offer a breakthrough to retinal disease sufferers?
- Could a new gene-editing technology permanently cure Duchenne muscular dystrophy?
Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis
Ocrevus (ocrelizumab) is a humanised monoclonal antibody indicated for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Oncology: the ups and downs of enrollment in China
GlobalData found that Oncology was the largest therapy area for clinical trials in China. Infectious Disease was the second largest area, followed by Cardiovascular, Metabolic Disorders, and Central Nervous System.
AACR 2018: revisiting murine models to develop drug combos for KRAS-driven cancers
Treatment of KRAS-driven cancers is among one of the highest unmet needs in the oncology space.
Lack of CMO availability threatens cell and gene therapy development
With a lack of contract manufacturing organizations (CMOs) operating in the cell and gene therapies sphere, it appears to be heading towards major capacity crunches in both R&D and commercial manufacturing.
Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis
Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.
Zubsolv (Buprenorphine and Naloxone) – Maintenance Treatment for Opioid Dependence
Zubsolv (buprenorphine and naloxone) is a sublingual tablet indicated as maintenance treatment for people suffering from opioid dependence.
Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma
Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in patients with a positive BRAF V600 mutation who were previously treated and made progresssion with Yervoy (ipilimumab).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.